https://doi.org/10.17952/37EPS.2024.P2293



MOLECULAR INSIGHTS INTO THE LIPID BILAYER INTERACTIONS OF THE CYCLIC LIPODEPSIPEPTIDE TOLAASIN <u>B. Kovács¹</u>, T. Juhász¹, N. Geudens², José C. Martins² and T. Beke-Somfai¹



¹BIOMOLECULAR SELF-ASSEMBLY GROUP, HUN-REN RESEARCH CENTRE FOR NATURAL SCIENCES, BUDAPEST, HUNGARY

²NMR AND STRUCTURE ANALYSIS RESEARCH UNIT, DEPARTMENT OF ORGANIC AND MACROMOLECULAR CHEMISTRY, GHENT UNIVERSITY

Tolaasin – not your average AMP



II) Tolaasin membrane interaction characterized by polarized light





vs Toxin of Brown Blotch Disease^[5] \times



Few (left) vs many (right) tolaasin producers in soil of cocoyam crop fields in Cameroon



Decreases production in edible mushroom farms of *Agaricus bisporus* by 8–15% in Europe

amphipathic surface

Figure adapted from [5]

Antifungal activity via cell membrane interactions. Main mode of action?

 \rightarrow Mixed reports i.e. barrel-staved pore formation^[2,6] vs asymmetry stress^[7]



Oliver of the second se

Via Ion Channel Measurements + ATR-IR

Oligomer vs Monomer (high *P/L*) (low *P/L*)

Adapted from [7b]

Via Fluorescence Leakage

→ Objective: molecular insights into the interaction of tolaasin and the lipid bilayer using novel biophysical and computational approaches.



Results II

- Tolaasin maintains its α_L -helical conformation upon interaction with lipid bilayers regardless of their charge.
- With negatively charged, (4:1) mixed DOPC-DOPG vesicles the α-helix of tolaasin is inserted into the lipid bilayer more parallel with its surface norm. Using P/L=1:10 LD signal of tolaasin shows gradual increase that plateaus on the timescale of hours and remains constant.
- Conditions are crucial! Using zwitterionic liposomes or lower *P/L* ratio tolaasin remains weakly aligned suggesting more random orientation within the lipid bilayer or transient alignment.

Discussion and Outlook

- Isotopically labeled NMR methods allowed to quantify backbone torsion angles and directly detect long-lived backbone hydrogen bonds for the cyclic lipodepsipeptide tolaasin. These data can now be implemented as novel restraints to improve the current model of tolaasin oligomerization and pore formation processes.
- Polarized light spectroscopy confirmed that the tolaasin helix is able to insert itself into the lipid bilayer parallel with the surface norm which agrees with ATR-IR results^[6c]. The full insertion process takes place gradually on the timescale of *hours* and shows irreversible provided that, in our setup, 20% negatively charged SUVs and high peptide-to-lipid ratio (1:10) are used. To demonstrate potential oligomerization and pore formation processes under these conditions imaging techniques are planned to be involved. However, in general, at low *P/L* values or min timescale insertion of the tolaasin helix into the lipid bilayer is yet inefficient and no pore formation is expected.^[7b]

III) Initial molecular dynamics simulations of the lipid bilayer interactions of tolaasin

• AMBER ff14SB force field^[13], TIP3P water solvent, lipid bilayer builder: CHARMM-GUI Membrane Builder^[14]

 \rightarrow setup: 2 tolaasin +128 POPC molecules (*P/L*=64), 100 ns

Observations

• The tolaasin molecules remain parallel with the surface.



Abbreviations

 Δ But – dehydroaminobutyril, AMP – antimicrobial peptide, ATR-IR – attenuation total reflection infrared spectroscopy DAB – 2,4 diaminobutyril, DMSO – dimethyl sulfoxide, DOPC – 1,2-dioleoyl-sn-glycero-3-phosphocholine or (18:1) PC, DOPG – 1,2-dioleoyl-sn-glycero-3-phosphoglycerol or (18:1) PG, DPC – dodecyl phosphocholine, HNHA – experiment [8], Hse – homoseryl, LD – linear dichroism, LR-HNCO – long-range HNCO experiment [9], MOA – mode of action, NRPS – non-ribosomal peptide synthetase, NMR – nuclear magnetic resonance, PBS – phosphate buffer saline solution, *P/L* – molar peptide to lipid ratio, retA – retinoic acid, SDS – sodium dodecyl sulfate, SUV – small unilamellar vesicle

References

[1] Nutkins, J.C. *et al.*, *JACS*, 1991, **113**, 2621–2627. [2] Jourdan, F. *et al.*, *Proteins: Struct., Funct., Genet.*, 2003, **52**, 534–543 [3] Geudens, N., Martins., J.C. *Front. Mirobiol.* 2018, **9**, 1–18 C. [4] Olorunleke, F.E. *et al.* unpublished data [5] Soler-Rivas, S. *et al.*, *FEMS Microbiol. Rev.*, 1999, **23**, 591–614. [6] a) Cho, K.H. and Kim, Y. K., *FEMS Microbiol. Lett.*, 2003, **221**, 221–226. b) Brody, C.L. *et al.*, *Mol. Plant Microb. Interact.* 1991, **4**, 407–411. c) Coraiola, M. *et al.*, *BBA*, 2006, **1758**, 1713–1722. d) Jo, G. *et al.*, *J. Microbiol. Biotechnol.*, 2011, **21**, 1097–1100. [7] a) Andolfi, A. *et al.*, *Perspect. Med. Chem.*, 2008, **2**, 1177391X0800200–112. b) Steigenberger, J. *et al.*, *Front.*, *Mol.*, *Biosci.*, 2022, **9**, 2296-889X. [8] Vuister, G.W. and Bax, A., *JACS*, 1993, **115**, 7772–7777. [9] Cordier, F. *et al.*, *Nat. Protoc.*, 2008, **3**, 235–241. [10] Geudens, N. *et al. Molecules*, 2019, **24**, 2257. [11] Nordén, B. *et al.*, Linear Dichroism and Circular Dichroism: A Textbook on polarized-light spectroscopy, *RSC Books*, Cambridge, UK, 2010. [12] Svensson, F.R. *et al.*, *J. Phys. Chem. B*, 2007, **111**, 10839–48. [13] Maier, J.A. *et al.*, *J. Chem. Theory Comput.*, 2015, **11**, 3696–3713. [14] a) Jo, S. *et al.*, *PLoS ONE*, 2007, **2**, e880. b) Jo, S. *et al.*, *Biophys J.*, 2009, **97**, 50–58.

Group platform: http://bionano.ttk.mta.hu/

e-mail: kovacs.benjamin@ttk.hu